Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic ... (ure frequency wassustained over the one-...)

Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)

Date:6/28/2009

ure frequency was sustained over the one-year open label treatment period and was consistent regardless of baseline therapy.

Tolerability

The safety profile of ESL was favourable. The majority of treatment related adverse events were mild or moderate in intensity. After 6 weeks of treatment, there were no observed differences in the incidence of side effects between patients treated with ESL and the placebo group.

Quality of life and depressive symptoms

The effect of ESL on quality of life was assessed using the Quality of Life Epilepsy Inventory-31 (QOLIE-31) scale. There was a statistically and clinically significant improvement from baseline during long-term open-label therapy, including a mean relative improvement in overall quality of life (p<0.001 - p<0.01 across the three studies) and improvements in individual elements of the QOLIE-31 scale including seizure worry, emotional wellbeing, energy/fatigue, medication effects and social function(8).

Improvement in depressive symptoms was also measured using the Montgomery Asberg Depression Rating Scale (MADRS). During long-term, open-label therapy, ESL demonstrated a statistically significant improvement from baseline in the overall MADRS score (p<0.0001) and individual domains of the MADRS scale including pessimistic thoughts, concentration difficulties, apparent sadness and inner tension(8).

These data were presented at the 28th International Epilepsy Congress held in Budapest, 28 June 2009 - 2 July 2009, the 8th European Congress on Epileptology held in Berlin last September 2008 and at the Annual Meeting of the American Epilepsy Society (AES) in December 2008, Seattle, WA, USA.

About BIAL

Founded in 1924, BIAL is an international pharmaceutical group with products available in over 30 countries throughout four continents. BIAL is the largest Portuguese pharmaceutical com
'/>"/>

SOURCE BIAL
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
2. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
3. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
4. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
5. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
6. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
9. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
10. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
11. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial

Post Your Comments:

(Date:12/14/2009)... Associates, a leading public affairs agency providing ... issues management, today announced that it has ... PSID ) to serve as the ... Associates will conduct media relations for PositiveID,s ... its public relations programs. ,, PositiveID, headquartered ...

(Date:12/14/2009)... Pa., Dec. 14 At GeoInvesting.com, we have ... for some time now. Our largest hang up had ... the Company,s fiscal June 2010 net income guidance of ... 2009 reported net income of $7.9 million, the increase ... EPS growth scenario, which depends upon the share price ...

(Date:12/14/2009)... Dec. 14 When staff from a ... apply the difficult to adjust and uncomfortable cubital ... Professional Products, Inc. (PPI) to develop a superior ... orthopaedic solutions for nearly five decades, responded with ... ), which it announced today. Simple to ...

Breaking Medicine Technology:Gibraltar Associates Named Agency of Record for Health Information and Diagnostic Provider PositiveID Corporation 2 GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms 2 New Cubital Tunnel Splint Specially Designed for Comfort and Less Cumbersome Fit 2 New research shows dinosaurs may have been smaller than we thought 9003 1 New research shows dinosaurs may have been smaller than we thought 9003 2 Innovative Psoriasis Treatment PSORENT 28R 29 Announces Healthcare Cost Savings Potential Consistent with President Obamas Announcement on Healthcare 4651 1 Innovative Psoriasis Treatment PSORENT 28R 29 Announces Healthcare Cost Savings Potential Consistent with President Obamas Announcement on Healthcare 4651 2 Respiratory Rally a Promising Practice in the Fight Against Chronic Disease 50062 1 Respiratory Rally a Promising Practice in the Fight Against Chronic Disease 50062 2

[0] Gibraltar Associates Named Agency of Record for Health Information and Diagnostic Provider PositiveID Corporation [0] GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms [0] New Cubital Tunnel Splint Specially Designed for Comfort and Less Cumbersome Fit

... to Advance to Phase Three Trials FRAZER, Pa., March ... CEPH ) today announced positive results from a phase ... adjunctive therapy for treating major depressive disorder in adults ... American adults are affected by bipolar I disorder, which ...

... Today at 5:00 p.m. Eastern Time - SOUTH SAN ... PARD ), a biopharmaceutical company focused on ... and year ended December 31, 2008, and provided a ... made significant progress toward our goal of developing picoplatin ...

Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update

(Date:12/14/2009)... In today,s academic medical centers, value ... Now the University HealthSystem Consortium (UHC) has created ... Achieving Cost Efficiencies in Health Care, to ... These new materials, developed with the input of ... practical guide to planning, implementing, and managing all ...

(Date:12/14/2009)... Fla., Dec. 14 Abbott (NYSE: ... definitive agreement to acquire STARLIMS Technologies Ltd. ... of laboratory information management systems, for approximately ... acquisition strengthens Abbott,s competitive position in the ... to help laboratories efficiently store, retrieve and ...

(Date:12/14/2009)... Aflac Incorporated announced today that it has priced ... with a coupon of 6.9%. The notes will ... yield 6.984%. The company anticipates using the proceeds ... corporate purposes. ,, Commenting on the pricing of ... Financial Officer Kriss Cloninger III commented: "This debt ...

(Date:12/14/2009)... researchers say , , MONDAY, Dec. 14 (HealthDay News) -- ... a single gene linked to heart failure. , The ... Louis analyzed the DNA of a large group of ... in four genes that could be connected with heart ... and 625 healthy whites led the researchers to identify ...

(Date:12/14/2009)... procedures vary widely and are higher than generally thought, raising concerns ... by University of California, San Francisco (UCSF) imaging specialists. ... ... -- Radiation doses from common CT procedures vary widely and are ... according to a new study led by University of California, ...

Breaking Medicine News(10 mins):Health News:University HealthSystem Consortium Offers Value Analysis Professionals Insightful New Resources 2 Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 2 Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 3 Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 4 Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 2 Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 3 Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 4 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 2 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 3 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 4 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 5

[1] University HealthSystem Consortium Offers Value Analysis Professionals Insightful New Resources [0] Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems [0] Aflac Incorporated Prices $400 Million of 30-Year Senior Notes [0] Contributors to Heart Failure Identified [0] Variable Doses of Radiation Raise Safety Concerns for CT Procedures

... Kensey Nash Corporation,(Nasdaq: KNSY ) is scheduled ... at the Grand Hyatt New York Hotel in New ... Evans, Kensey Nash,s COO, will deliver the Company,s,presentation, beginning ... of the Kensey Nash presentation at the FBR conference, ...

... in Discovery Green Park, HOUSTON, May 23 ... year,s presidential election and the cost of health care,continuing ... (HJMHF) will offer Houston residents a fun and informative,opportunity ... The multicultural health event, which will kick off ...

... 32, was indicted by a grand jury in ... the operation of an,illegal Internet pharmacy, Assistant Attorney ... U.S. Attorney Patrick L. Meehan for the,Eastern District ... charged with four counts of distribution of controlled,substances ...

... risk, healthy eating and exercise can delay disease, researchers say ... programs for people at high risk for developing diabetes, when ... diabetes for 14 years after the programs end, a new ... 24 special diabetes issue of The Lancet . , ...

... cause of some forms of vision loss , ... protease inhibitors has been suggested by a team of researchers ... a result of their work in a mouse model of ... many diseases of the eye is the death (by a ...

... CRGN ) announced today the completion of ... Company sold the 5,000,000 shares of,TopoTarget common stock ... the,sale of CuraGen,s ownership in belinostat. After expenses, ... "We are pleased to announce the planned, orderly ...

Kensey Nash to Participate in the Friedman Billings Ramsey 12th Annual Spring Investor Conference Announcing the 2nd Annual Houston Juneteenth Multicultural Health Festival California Man Indicted For Conspiracy In Operating Internet Pharmacy Lifestyle Changes Can Keep Diabetes at Bay for 14 Years JCI table of contents: May 22, 2008 CuraGen Sells 5 Million TopoTarget Shares for Approximately $12 Million

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

Medicine Products:

Vancomycin, Trough Level Vancor, Random Level Vancocin, Trough Level Vancomycin, Random Level

Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic ...(ure frequency wassustained over the one-...),Health